Security
DelMar Pharmaceuticals, Inc. Common Stock · DMPI
DMPIOTCCommon stockHistorical · closed May 20, 2016CIK 1498382Updated Oct 19, 2026
Name history
Kintara Therapeutics, Inc. · through Oct 22, 2024DelMar Pharmaceuticals, Inc. · through Aug 18, 2020Berry Only Inc. · through Jan 18, 2013
Current security for this SEC filerHURA · NASDAQ
DMPI price & chart
Historical security
This listing closed May 20, 2016. Live provider charts are shown only for current listings.
Current security: HURA
About the company
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer. TuHURA’s lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
In the news
No coverage from other publishers is available.
Recent filings
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 2.03, 9.01
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 2.03, 9.01
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 2.03, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Show 5 more recent filings
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 2.03, 9.01
SCHEDULE 13D/A - filed by Bianco James A. regarding TuHURA Biosciences, Inc./NV
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 2.03, 9.01
Unregistered Sales of Equity Securities · Submission of Matters to a Vote of Security Holders
Items 3.02, 5.07, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | — | 7,446,000Source | 6,740,000Source | 27,353,156Source | 19,966,684Source | 1,885,000Source | 4,140,000Source | 1,477,000Source | 27,353,156Source | 19,966,684Source | 3,979,000Source | 15,948,000Source |
| Property, Plant and Equipment, NetUSD | — | 691,000Source | 724,000Source | 300,639Source | 123,366Source | 699,000Source | 657,000Source | 694,000Source | 300,639Source | 123,366Source | 709,000Source | 90,000Source |
| GoodwillUSD | — | — | — | 10,738,082Source | — | — | — | — | 10,738,082Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 6,351,000Source | 3,045,000Source | 3,619,949Source | 12,657,178Source | 658,000Source | 3,020,000Source | 216,000Source | 3,619,949Source | 12,657,178Source | 1,535,000Source | 11,780,000Source |
| Assets, CurrentUSD | — | 6,755,000Source | 6,016,000Source | 4,621,136Source | 19,610,389Source | 1,186,000Source | 3,483,000Source | 783,000Source | 4,621,136Source | 19,610,389Source | 3,270,000Source | 13,258,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | 384,530Source | 199,160Source | — | — | — | 384,530Source | 199,160Source | — | — |
| Other Assets, NoncurrentUSD | — | — | — | 33,769Source | 33,769Source | — | — | — | 33,769Source | 33,769Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | 1,524,000Source | 2,954,000Source | 6,420,828Source | 5,372,708Source | 2,049,000Source | 2,445,000Source | 3,503,000Source | 6,420,828Source | 5,372,708Source | 3,248,000Source | 4,153,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | — | 55,000Source | 2,000Source | 59,336Source | 42,324Source | 10,000Source | 2,000Source | 2,000Source | 59,336Source | 42,324Source | 2,000Source | 66,000Source |
| Retained Earnings (Accumulated Deficit)USD | — | -157,550,000Source | -148,038,000Source | -141,184,902Source | -111,124,569Source | -155,537,000Source | -162,052,000Source | -154,512,000Source | -141,184,902Source | -111,124,569Source | -151,375,000Source | -136,356,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 21,000Source | 21,000Source | — | — | 21,000Source | 21,000Source | 21,000Source | — | — | 21,000Source | 21,000Source |
| Stockholders' Equity Attributable to ParentUSD | 9,856,463Source | -6,066,284Source | 3,786,000Source | 20,932,328Source | 14,593,976Source | -1,558,746Source | 1,695,000Source | -2,026,000Source | 20,932,328Source | 14,593,976Source | 731,000Source | 11,795,000Source |
| Additional Paid in Capital, Common StockUSD | — | 153,144,000Source | 141,156,000Source | 161,779,364Source | 125,397,691Source | 145,090,000Source | 163,445,000Source | 141,855,000Source | 161,779,364Source | 125,397,691Source | 141,438,000Source | 135,510,000Source |
| Liabilities and EquityUSD | — | 7,446,000Source | 6,740,000Source | 27,353,156Source | 19,966,684Source | 1,885,000Source | 4,140,000Source | 1,477,000Source | 27,353,156Source | 19,966,684Source | 3,979,000Source | 15,948,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | — | 1,341,000Source | 2,790,000Source | 5,919,282Source | 5,330,010Source | 1,870,000Source | 2,257,000Source | 3,336,000Source | 5,919,282Source | 5,330,010Source | 3,082,000Source | 3,990,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | 199,041Source | 159,844Source | — | — | — | 199,041Source | 159,844Source | — | — |
| Accounts Payable, CurrentUSD | — | — | — | 3,770,124Source | 3,152,816Source | — | 1,871,000Source | — | 3,770,124Source | 3,152,816Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | 303,627Source | 42,698Source | — | — | — | 303,627Source | 42,698Source | — | — |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | 197,919Source | — | — | — | — | 197,919Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | 1,525,139Source | 1,161,650Source | — | 336,000Source | — | 1,525,139Source | 1,161,650Source | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 197,919Source | 51,174Source | — | — |
cash flow · annual statements
| Line item | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -2,011,000Source | — | — | -1,023,000Source | -2,161,000Source | -2,962,000Source | -30,051,977Source | -21,682,306Source | -14,649,000Source | -22,661,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | 71,265Source | 116,710Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | 6,424,730Source | 1,958,663Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,889,000Source | -1,317,000Source | -27,629,150Source | -14,728,138Source | -11,865,000Source | -20,392,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -1,335,361Source | -6,052,409Source | -232,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 76,083Source | 57,906Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | -2,000Source | 19,927,282Source | 29,772,693Source | 1,852,000Source | 21,635,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,889,000Source | -1,319,000Source | -9,037,229Source | 8,992,146Source | -10,245,000Source | 1,243,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 6,351,000Source | 3,619,949Source | 12,657,178Source | 3,665,032Source | 3,020,000Source | 216,000Source | 3,619,949Source | 12,657,178Source | 1,535,000Source | 11,780,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 59,364Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 156,000Source | — | — | 165,000Source | 98,000Source | 160,000Source | 6,424,730Source | 1,958,663Source | 1,490,000Source | 2,248,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 3,225,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | 17,000Source | 15,000Source | 71,000Source | 117,000Source | 60,000Source | 60,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | — | — | -6,000Source | -1,000Source | -2,000Source | — | — | 10,000Source | 7,000Source |
| General and Administrative ExpenseUSD | — | — | 1,493,000Source | — | — | 908,000Source | 1,957,000Source | 1,103,000Source | 7,583,651Source | 4,314,176Source | 5,485,000Source | 7,509,000Source |
| GoodwillUSD | — | — | — | 10,738,082Source | — | — | — | — | 10,738,082Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,600Source | 3,768Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | -6,664,371Source | -4,842,142Source | — | — | -1,023,000Source | -2,161,000Source | -2,962,000Source | -30,051,977Source | -21,682,306Source | -14,649,000Source | -22,661,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -2,013,000Source | — | — | -1,025,000Source | -2,176,000Source | -3,137,000Source | -30,060,333Source | -22,649,572Source | -15,019,000Source | -25,131,000Source |
| Nonoperating Income (Expense)USD | — | — | 74,000Source | — | — | -4,000Source | 48,000Source | 0Source | — | — | 147,000Source | 21,000Source |
| Operating ExpensesUSD | — | — | 2,085,000Source | — | — | 1,019,000Source | 2,209,000Source | 2,962,000Source | 31,795,939Source | 17,649,492Source | 14,796,000Source | 22,682,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 172,000Source | 163,000Source | 39,000Source | 41,400Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 1,743,962Source | -4,032,814Source | — | — |
| Other Operating Income (Expense), NetUSD | — | — | 74,000Source | — | — | 2,000Source | 49,000Source | 2,000Source | — | — | 137,000Source | 14,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 18,303,312Source | 5,000,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 104,000Source | — | — |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | 98,000Source | 160,000Source | — | — | 1,490,000Source | 2,248,000Source |
income statement · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 1,743,962Source | -4,032,814Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -30,051,977Source | 21,700,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,600Source | 3,768Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,664,371Source | -4,842,142Source | -3,264,000Source | -1,023,000Source | -2,161,000Source | -2,962,000Source | -30,051,977Source | -21,682,306Source | -14,649,000Source | -22,661,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | -0.05Source | -1.94Source | -0.24Source | -1.37Source | -63.92Source | -0.63Source | -1.21Source | -9.27Source | -0.52Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | — | — | — | — | -0.63Source | -1.21Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | 44,562,000Source | 1,681,000Source | 4,337,000Source | 1,586,000Source | 49,000Source | 47,927,196Source | 18,662,690Source | 1,620,000Source | 48,702,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | — | — | — | — | 47,927,196Source | 18,662,690Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 3,225,000Source | — |
| Business Combination, Acquisition Related CostsUSD | — | — | — | — | — | — | — | — | 3,679,618Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,600Source | 3,768Source | 0Source | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 0Source | -1,000Source | -6,000Source | -1,000Source | -2,000Source | — | — | 10,000Source | 7,000Source |
| General and Administrative ExpenseUSD | — | — | — | 1,493,000Source | 1,297,000Source | 908,000Source | 1,957,000Source | 1,103,000Source | 7,583,651Source | 4,314,176Source | 5,485,000Source | 7,509,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -30,051,977Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | 625,283Source | 4,138,301Source | — | — |
| Interest Income, OtherUSD | — | — | — | — | — | — | — | — | 136,233Source | 361,632Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -2,013,000Source | -3,266,000Source | -1,025,000Source | -2,176,000Source | -3,137,000Source | -30,060,333Source | -22,649,572Source | -15,019,000Source | -25,131,000Source |
| Nonoperating Income (Expense)USD | — | — | — | 74,000Source | 38,000Source | -4,000Source | 48,000Source | 0Source | — | — | 147,000Source | 21,000Source |
| Operating ExpensesUSD | — | — | — | 2,085,000Source | 3,302,000Source | 1,019,000Source | 2,209,000Source | 2,962,000Source | 31,795,939Source | 17,649,492Source | 14,796,000Source | 22,682,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 172,000Source | 163,000Source | 39,000Source | 41,400Source |
| Other Operating Income (Expense), NetUSD | — | — | — | 74,000Source | 39,000Source | 2,000Source | 49,000Source | 2,000Source | — | — | 137,000Source | 14,000Source |
| Research and Development ExpenseUSD | — | — | — | 592,000Source | 2,005,000Source | 111,000Source | 252,000Source | 1,859,000Source | 20,532,670Source | 13,335,316Source | 9,311,000Source | 15,173,000Source |
| Preferred Stock Dividends and Other Adjustments | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
Offerings
Registration 333-289532
Registration 333-284787
Filing attachments
hura-ex99_1.htm · 8-K · 2026-08-14
EX-99.1 2 hura-ex99_1.htm EX-99.1 EX-99.1 TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update TAMPA, Fla., August 14, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update. “We have made signific…
Read attachment ↗hura-ex99_1.htm · 8-K · 2026-05-15
EX-99.1 2 hura-ex99_1.htm EX-99.1 EX-99.1 TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update TAMPA, Fla., May 15, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended March 31, 2026, and provided a corporate update. “I am very pleased with th…
Read attachment ↗d150994dex991.htm · 8-K/A · 2026-04-30
EX-99.1 2 d150994dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Unless the context indicates otherwise in this Unaudited Pro Forma Condensed Combined Financial Information, references to “TuHURA,” “TuHURA Biosciences, Inc.” the “Company,” “we,” “us,” “our” and similar terms refer to TuHURA Biosciences, Inc., a Nevada corporation (and our predecessor company) and its consolidated subsidiaries. Capitalized terms included but not defined …
Read attachment ↗d139552dex41.htm · 8-K · 2026-04-22
EX-4.1 2 d139552dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 Execution Version Loan Agreement between TUHURA BIOSCIENCES, INC., as Borrower and PARKVIEW HOLDINGS ONE LLC, as Lender dated as of April 21, 2026 TABLE OF CONTENTS ARTICLE I Definitions and Interpretation 7 Section 1.01 Definitions 7 Section 1.02 …
Read attachment ↗d139552dex991.htm · 8-K · 2026-04-22
EX-99.1 7 d139552dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestones TAMPA, Fla., April 22, 2026 - TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therap…
Read attachment ↗